CN112439122A - Balloon dilatation catheter - Google Patents
Balloon dilatation catheter Download PDFInfo
- Publication number
- CN112439122A CN112439122A CN201910836634.3A CN201910836634A CN112439122A CN 112439122 A CN112439122 A CN 112439122A CN 201910836634 A CN201910836634 A CN 201910836634A CN 112439122 A CN112439122 A CN 112439122A
- Authority
- CN
- China
- Prior art keywords
- balloon
- layer
- tube
- far
- catheter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000017531 blood circulation Effects 0.000 claims abstract description 26
- 229910052751 metal Inorganic materials 0.000 claims abstract description 12
- 239000002184 metal Substances 0.000 claims abstract description 12
- 210000003128 head Anatomy 0.000 claims abstract description 10
- 230000007704 transition Effects 0.000 claims abstract description 9
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims abstract description 8
- 239000004810 polytetrafluoroethylene Substances 0.000 claims abstract description 8
- 210000005077 saccule Anatomy 0.000 claims abstract description 8
- 229920000642 polymer Polymers 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 46
- 229940079593 drug Drugs 0.000 claims description 31
- 238000000576 coating method Methods 0.000 claims description 23
- 229920002614 Polyether block amide Polymers 0.000 claims description 22
- 239000011248 coating agent Substances 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 22
- 230000010339 dilation Effects 0.000 claims description 14
- 239000004677 Nylon Substances 0.000 claims description 11
- 229920001778 nylon Polymers 0.000 claims description 11
- 229920001971 elastomer Polymers 0.000 claims description 10
- 239000000806 elastomer Substances 0.000 claims description 10
- 229920002635 polyurethane Polymers 0.000 claims description 9
- 239000004814 polyurethane Substances 0.000 claims description 9
- 230000002792 vascular Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 6
- 239000012752 auxiliary agent Substances 0.000 claims description 5
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- -1 Polytetrafluoroethylene Polymers 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 3
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims description 3
- 229960002603 iopromide Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 abstract description 18
- 208000028867 ischemia Diseases 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 208000014674 injury Diseases 0.000 abstract description 4
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000007917 intracranial administration Methods 0.000 description 5
- 201000008450 Intracranial aneurysm Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 238000005452 bending Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 230000002966 stenotic effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004944 Liquid Silicone Rubber Substances 0.000 description 1
- 229920000106 Liquid crystal polymer Polymers 0.000 description 1
- 239000004977 Liquid-crystal polymers (LCPs) Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a balloon dilatation catheter which comprises a soft head, a balloon, an inner tube, a far-end outer tube, a transition tube, a hypotube and a catheter handle. The combination body of the soft head and the inner tube is arranged in and connected with the far-end neck of the saccule, and the inner tube penetrates through the inner cavity of the far-end outer tube and the inner cavity of the saccule; the distal-most end of the distal outer tube is placed into and attached to the proximal neck of the balloon. The balloon surface is provided with one or more blood flow guiding grooves along the axial direction. The inner pipe is of a multilayer structure, the outer layer is a polymer layer with gradually changed hardness, the middle layer is a metal net, and the inner layer is PTFE. The balloon is provided with the blood flow guide groove, so that the blood flow cannot be completely blocked when the balloon is inflated, and the injury caused by ischemia of a far-end blood vessel and a far-end tissue is avoided; the far ends of the saccule and the catheter are very flexible, the operation performance is good, the penetrating performance is strong, and therefore the operation is rapid, the cost is saved, and the risk to the patient is small.
Description
Technical Field
The invention belongs to medical instruments, and particularly relates to a balloon dilatation catheter.
Background
Cerebrovascular disease is the most common and serious disease threatening human life and health. Wherein, the cerebral apoplexy is the first cause of death in China. Research data shows that 330 million new stroke patients occur in China each year, the number of stroke death patients is about 170 million each year, the treatment cost for the stroke is over 100 million yuan each year in China, and heavy economic burden is caused to the nation and families. Cerebral aneurysm refers to intracranial aneurysm, with hidden course, sudden onset, and high disability and mortality rate once it occurs, and is called intracranial "sporadic bomb" which is one of the most dangerous cerebrovascular diseases. The number of new cerebral aneurysm patients in China is as much as 20 ten thousand every year. For cerebral apoplexy and cerebral aneurysm, the treatment with drugs is almost ineffective. Although the craniotomy has good curative effect, the intracranial vascular structure is complex, so that the surgery is very limited and has great risks. With the continuous development of minimally invasive interventional therapy, the interventional therapy technology of intracranial vascular diseases is more and more advanced, and methods such as intracranial vascular stent forming operation, intravascular stent thrombus removal, suction catheter thrombus removal treatment and the like have brought great benefits to patients. However, interventional procedures often involve stenotic vessels, such as when a stent or a thrombus aspiration catheter is inserted, and the stenotic vessels are likely to be unable to pass through during stent delivery, so that the stenotic vessels need to be pre-expanded by a balloon dilatation catheter for smooth passage of the stent or other therapeutic devices. Because intracranial vessels are small in tortuosity and complex in structure, the far end of the balloon dilatation catheter is required to have very good flexibility and fracture resistance. On the other hand, the balloon inflated at high pressure is closely attached to the vessel wall, so that blood flow is blocked, and then far-end blood vessel ischemia is caused, brain tissue death is caused, great risk is brought to a patient, and even the life of the patient is threatened. Thus, an ideal intracranial balloon dilation catheter should have very good compliance and resistance to flexing, while not completely blocking blood flow.
The advent of vascular stents opened a new era for vascular therapy. But In Stent Restenosis (ISR) is a significant problem. If another stent is released within the restenosis drug stent, the incidence of subsequent restenosis can be as high as 43%. The superiority of Drug-coated balloons (DCB), a combination of traditional balloon angioplasty and advanced Drug elution techniques, is increasingly shown. DCB is not only simple and convenient to operate, but also has unique advantages on stent restenosis, bifurcation lesion, small vessel lesion, severe bending calcification lesion and the like. While DCB has many potential advantages, it has several significant problems:
1. to ensure adequate penetration of the drug into the vessel or tissue, DCB is generally maintained in a full state for more than one minute, but conventional balloon dilation procedures for coronary and peripheral vessels limit balloon dilation times (blood flow blocking times) to no more than a few tens of seconds. The problems of short contact time of DCB and pathological tissues and low drug transfer rate are urgently solved.
2. Because the existing drug coating carrier material and balloon material have insufficient bonding force, the drug on the surface of the balloon is seriously lost in the intervention process.
3. The existing drug coating carrier material has general blood compatibility and can generate negative effect on blood vessel healing.
In order to solve the above problems, some modifications of the structure, composition and drug delivery manner of DCB have been made by those skilled in the art, for example, chinese patent application 201510378938.1 provides a drug balloon catheter, in which a first cavity and a second cavity are arranged in the inner cavity of the catheter body along the axial direction of the catheter body, and the first cavity and the second cavity penetrate through the catheter body where the balloon portion is arranged; wherein the first cavity is used for a guide wire to pass through; the second lumen is for the passage of blood. However, due to the design, the aperture of the second cavity is small, and the unobstructed blood flow cannot be ensured. Chinese patent application 201610186716.4 provides a balloon catheter for blocking blood flow, describing a balloon consisting of a four petal shaped balloon. This design can provide adequate blood flow lumen, but the significant drawback is that the gaps between the petal balloons are too large and the plaque or emboli that sloughed off during the vasodilation procedure can flow to and occlude the distal vessel, posing a significant risk to the patient. To address the problem of drug loss from the balloon surface during the intervention, chinese patent application 201310535041.6 describes a double-layered balloon in which one layer is a porous structure. The balloon of this design is complex in structure, very costly to manufacture, and requires many less hemocompatible chemicals, such as one of silica or starch as the filler, and hydrophilic polar monomers (one of acrylic acid, methacrylic acid, acrylamide, acrylate, methacrylate, hydroxyethyl methacrylate, vinyl acetate, or acrylonitrile).
In fact, some unsaturated fatty acids which are good in blood compatibility and beneficial to human bodies have good affinity with balloon materials, and are good in compatibility and fitting with blood vessels. For example, linoleic acid is not synthesized by humans, but it lowers blood cholesterol and prevents atherosclerosis. Omega-3 fatty acid is also very beneficial to human body, and more than 1.5 ten thousand research reports show that Omega-3 fatty acid has the characteristics of anti-inflammation, anti-thrombosis, anti-cardiac rhythm, blood fat reduction and blood vessel relaxation.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the balloon dilatation catheter which can avoid the risks brought to the patient due to balloon dilatation and far-end blood vessel ischemia. The balloon is provided with the blood flow guide groove, so that the blood flow cannot be completely blocked when the balloon is inflated, and the injury caused by ischemia of far-end blood vessels and tissues is avoided; the balloon and the balloon catheter have very soft and smooth far ends, good control performance and strong crossing performance, thereby having quick operation, cost saving and small risk to patients.
The technical scheme adopted by the invention for solving the technical problems is as follows:
a balloon dilation catheter, comprising: the device comprises a soft head, a balloon, an inner tube, a far-end outer tube, a transition tube, a hypotube and a catheter handle;
the combination body of the soft head and the inner tube is arranged in and connected with the far-end neck of the saccule, and the inner tube penetrates through the inner cavity of the far-end outer tube and the inner cavity of the saccule; the most distal end of the distal outer tube is arranged in the proximal neck of the balloon and is connected with the proximal neck of the balloon;
the balloon main body is provided with one or more blood flow guide grooves along the axial direction;
the inner pipe is of a multilayer structure, the outer layer is a polymer layer, the middle layer is a metal mesh, and the inner layer is Polytetrafluoroethylene (PTFE).
The outer layer of the inner tube is made of nylon, a block polyether amide elastomer Pebax or Polyurethane; the middle layer is a metal woven net or a spring net.
The hardness of the material of the far end of the outer layer of the inner pipe is lower than or equal to that of the material of the near end of the outer layer of the inner pipe, and the thickness of the material of the far end of the outer layer of the inner pipe is lower than or equal to that of the material of the near end of the outer layer of the inner pipe.
A drug coating is arranged on the surface of the balloon, and comprises a bottom layer and an outer layer; wherein the bottom layer is arranged on the surface of the balloon and is a mixture of a medicament and a medicament carrier; the outer layer is arranged above the bottom layer and is a drug coating auxiliary agent.
The medicine comprises: paclitaxel, rapamycin or a derivative of rapamycin, or a platelet inhibiting drug, or a vascular endothelialization inhibiting drug, or an anti-tumor drug;
the drug carrier comprises a biodegradable high molecular material, linoleic acid or Omega-3 fatty acid.
The drug coating auxiliary agent comprises: urea, iopromide, alcohols, amino acids or polyunsaturated fatty acids.
The far-end outer tube has a double-layer structure, and the outer layer is made of nylon or a block polyether amide elastomer Pebax or Polyurethane; the inner layer is a metal woven net or a spring net.
The far-end outer tube has a double-layer structure, and the outer layer is made of a block polyether amide elastomer Pebax or Polyurethane or ePTFE with low hardness; the inner layer is made of high-hardness nylon.
The outer surfaces of the distal outer tube and the transition tube are provided with hydrophilic coatings.
The invention has the beneficial effects that:
according to clinical requirements, the advantages of the scheme of the invention are summarized as follows:
1) when the balloon is used for dilating the narrow blood vessel, the blood flow can not be completely blocked due to the blood flow guide groove, so that the injury caused by ischemia of the far-end blood vessel and tissue is avoided;
2) the balloon and the far end of the balloon catheter are very flexible, the catheter has strong crossing performance, excellent bending resistance, good control performance, quick operation, small risk to patients and cost saving.
Drawings
FIG. 1 is a block diagram of a balloon dilation catheter;
FIG. 2 is a cross-sectional view of the balloon with a blood flow directing groove;
FIG. 3 is a cross-sectional view of another balloon with a blood flow directing groove;
FIG. 4 is a cross-sectional view of the balloon with two blood flow guide slots;
FIG. 5 is a schematic view of an inner tube of the present invention;
in the figure, 1. soft head; 2. a balloon; 3. a blood flow guide groove (balloon recess); 4. an inner tube; 5. a distal outer tube; 6, a transition pipe; 7. a hypotube; 8, supporting the stress tube; 9. a handle; 10. a hydrophilic coating; 11. and (4) coating the medicine.
Detailed Description
Example 1
As shown in fig. 1, the balloon dilation catheter of the embodiment includes: the device comprises a soft head 1, a balloon 2, a blood flow guide groove 3, an inner tube 4, a distal outer tube 5, a transition tube 6, a hypotube 7, a stress support tube 8, a catheter handle 9, a hydrophilic coating 10 and a drug coating 11.
The combination of the soft head 1 and the inner tube 4 is arranged in and connected with the neck part at the far end of the balloon 2, and the inner tube 4 penetrates through the inner cavity of the far-end outer tube 5 and the inner cavity of the balloon 2; the farthest end of the far-end outer tube 5 is placed in the neck part of the near end of the balloon 2 and is connected with the neck part of the near end of the balloon 2, so that the far-end outer tube 5 is communicated with the balloon 2;
the catheter handle 9 is connected with the far-end outer tube 5 through the hypotube 7 and the transition tube 6 and is communicated with the far-end outer tube 5, the balloon 2 can be filled at high pressure by injecting liquid from the filling cavity of the catheter handle 9, and the stress support tube 8 is further arranged between the catheter handle 9 and the hypotube 7 so as to ensure the anti-bending performance between the catheter handle 9 and the hypotube 7.
As shown in fig. 2, 3 and 4, the main body of the balloon 2 is provided with one or more blood flow guiding grooves 3 along the axial direction, i.e. the outer surface of the balloon has depressions when inflated. The balloon is provided with a blood flow guide groove, so that the filled balloon can not completely block blood flow, and the injury to far-end blood vessels and tissues is avoided;
the inner tube 4 is of a multilayer structure, and the outer layer is a high polymer layer with gradually-changed hardness, or nylon or a block polyether amide elastomer Pebax or Polyurethane; the middle layer is a metal reinforcing mesh or a spring mesh, and the inner layer is ultra-smooth PTFE, or high density polyethylene HDPE, or block polyether amide elastomer Pebax containing a friction coefficient reducing additive.
The outer surface of the distal outer tube 5 and the transition tube 6 is provided with a hydrophilic coating 10.
The balloon 2 surface may also be provided with a drug coating 11.
The far-end outer tube 5 has a double-layer structure, and the outer layer is made of nylon or a block polyether amide elastomer Pebax or Polyurethane; the inner layer is a metal woven net or a spring net.
The distal outer tube 5 may also be used: the outer layer is made of a low-hardness block polyether amide elastomer Pebax or Polyurethane or ePTFE; the inner layer is made of high-hardness nylon.
The soft head 1, the balloon 2, the inner tube 4 and the distal outer tube 5 at the distal end of the balloon dilatation catheter are very flexible, good in control performance and strong in crossing performance, so that the operation is fast, the cost is saved, and the risk to patients is small.
When the balloon dilatation catheter is used, a proper guide wire is pushed to a far-end blood vessel narrow section, the guide wire penetrates through a guide wire opening, the balloon dilatation catheter is pushed to enter a diseased blood vessel along the guide wire, when the balloon 2 in an unfilled state reaches the narrow section, liquid is injected from a catheter handle 9 filling cavity, the high-pressure filled balloon expands the narrow blood vessel, meanwhile, the medicine coating 11 on the surface of the balloon is attached to the blood vessel wall, and in order to transfer more medicines to the blood vessel wall and promote the medicine molecules to diffuse into the blood vessel wall, the balloon 2 is kept in a filled state for at least 2 minutes. Because the saccule 2 is provided with the two axial blood flow guide grooves 3 (as shown in fig. 3), the blood flow is not blocked in the drug transfer process, and the far-end blood vessel and the brain tissue cannot be damaged; on the other hand, since the axial blood flow guide groove is provided with a small cross section, a large thrombus is intercepted, and thus does not flow into and block the distal blood vessel.
Example 2
Based on example 1, the inner tube 4 of the balloon dilation catheter of the present invention is shown in fig. 5, and includes an outer layer proximal end 44, an outer layer distal end 43, a circular tubular intermediate metal mesh 42, and an ultra-thin Polytetrafluoroethylene (PTFE) tube inner layer 41. The guidewire passes through the guidewire lumen 12 to the distal vascular stenosis.
The wall thickness of the outer layer material of the inner tube 4 is gradually reduced or equal from the proximal end to the distal end, the outer diameter of the inner tube 4 is also gradually reduced or equal from the proximal end to the distal end, and the hardness of the inner tube 4 is also gradually reduced or equal from the proximal end to the distal end.
The material of the near end 44 of the outer layer of the inner tube is nylon or Pebax with higher hardness, and the material of the far end 43 of the outer layer of the inner tube is Pebax with lower hardness; the inner tube with the intermediate expanded metal 42 is superior in bending resistance, and such a design is well suited for very tortuous and soft cerebral vessels.
The woven mesh of the intermediate wire netting 42 is made of one or more of the following wire materials, including but not limited to: 1) Titanium alloy with tweezers; 2) A cobalt chromium alloy; 3) Stainless steel; 4) Pure platinum and its alloys; 5) Pure tungsten and its alloys. The wire material of the metal wire is a round wire or a flat wire. The diameter of the round wire, the thickness of the flat wire and the width are between 5 and 500 micrometers. The mesh grid can also be made of polymer wires made of nylon, PEEK, Liquid Crystal polymer or silicone rubber.
Example 3
As shown in fig. 1, on the basis of embodiment 1, a drug coating 11 is disposed on the surface of the balloon 2, and the drug coating 11 includes a bottom layer and an outer layer; wherein the bottom layer is arranged on the surface of the balloon and is a mixture of a medicament and a medicament carrier; the outer layer is arranged above the bottom layer and is a drug coating auxiliary agent.
The medicine is paclitaxel, rapamycin or rapamycin derivative, the drug-loading rate is 1-6 microgram/square millimeter, and can also be platelet inhibiting medicine, vascular endothelialization inhibiting medicine or antitumor medicine. The drug coating thickness is between 5-100 microns. The drug carrier is a material having good affinity with both the balloon material and the vessel wall, such as a biodegradable polymer material, or linoleic acid and Omega-3 fatty acid. The drug coating auxiliary agent is urea, iopromide, alcohol substances or amino acid or polyunsaturated fatty acid.
When the balloon 2 of the invention reaches the stenosis section, the liquid is injected from the filling cavity of the catheter handle 9, the balloon filled at high pressure expands the stenotic vessel, and the drug coating 11 on the surface of the balloon 2 is transferred and attached to the vessel wall because the carrier material and the vessel wall also have good affinity.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and variations can be made without departing from the technical principle of the present invention, and these modifications and variations should also be regarded as the protection scope of the present invention.
Claims (9)
1. A balloon dilation catheter, comprising: the device comprises a soft head, a balloon, an inner tube, a far-end outer tube, a transition tube, a hypotube and a catheter handle;
the combination body of the soft head and the inner tube is arranged in and connected with the far-end neck of the saccule, and the inner tube penetrates through the inner cavity of the far-end outer tube and the inner cavity of the saccule; the most distal end of the distal outer tube is arranged in the proximal neck of the balloon and is connected with the proximal neck of the balloon;
the balloon main body is provided with one or more blood flow guide grooves along the axial direction;
the inner pipe is of a multilayer structure, the outer layer is a polymer layer, the middle layer is a metal mesh, and the inner layer is Polytetrafluoroethylene (PTFE).
2. The balloon dilation catheter according to claim 1 wherein the outer layer of the inner tube is nylon, a block polyetheramide elastomer Pebax or Polyurethane; the middle layer is a metal woven net or a spring net.
3. The balloon dilation catheter according to claim 1 wherein the hardness of the inner tube outer layer distal material is lower than or equal to the hardness of the inner tube outer layer proximal material and the thickness of the inner tube outer layer distal material is lower than or equal to the thickness of the inner tube outer layer proximal material.
4. The balloon dilation catheter of claim 1 wherein a balloon surface is provided with a drug coating comprising a bottom layer and an outer layer; wherein the bottom layer is arranged on the surface of the balloon and is a mixture of a medicament and a medicament carrier; the outer layer is arranged above the bottom layer and is a drug coating auxiliary agent.
5. The balloon dilation catheter of claim 4 wherein the medicament comprises: paclitaxel, rapamycin or a derivative of rapamycin, or a platelet inhibiting drug, or a vascular endothelialization inhibiting drug, or an anti-tumor drug;
the drug carrier comprises a biodegradable high molecular material, linoleic acid or Omega-3 fatty acid.
6. The balloon dilation catheter of claim 4 wherein the drug coating adjuvant comprises: urea, iopromide, alcohols, amino acids or polyunsaturated fatty acids.
7. The balloon dilatation catheter of claim 1 or 4 wherein the distal outer tube has a double layer structure with an outer layer of material selected from nylon or a block polyetheramide elastomer Pebax or Polyurethane; the inner layer is a metal woven net or a spring net.
8. The balloon dilatation catheter of claim 1 wherein the distal outer tube has a double layer structure with outer layer material of low durometer block polyetheramide elastomer Pebax or Polyurethane or ePTFE; the inner layer is made of high-hardness nylon.
9. The balloon dilation catheter of claim 1 wherein the distal outer tube and transition tube outer surface have a hydrophilic coating.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910836634.3A CN112439122A (en) | 2019-09-05 | 2019-09-05 | Balloon dilatation catheter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910836634.3A CN112439122A (en) | 2019-09-05 | 2019-09-05 | Balloon dilatation catheter |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112439122A true CN112439122A (en) | 2021-03-05 |
Family
ID=74733420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910836634.3A Pending CN112439122A (en) | 2019-09-05 | 2019-09-05 | Balloon dilatation catheter |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112439122A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113144390A (en) * | 2021-04-26 | 2021-07-23 | 珠海通桥医疗科技有限公司 | Balloon catheter for intracranial CTO |
CN113368371A (en) * | 2021-06-03 | 2021-09-10 | 复旦大学附属中山医院 | Medicine carrying balloon for preventing and treating benign stricture of esophagus |
CN114939225A (en) * | 2022-06-10 | 2022-08-26 | 惠州市顺美医疗科技有限公司 | Balloon dilatation catheter |
WO2022198810A1 (en) * | 2021-03-25 | 2022-09-29 | 上海苏畅医疗科技有限公司 | Guiding catheter and guiding catheter system |
WO2022262490A1 (en) * | 2021-06-18 | 2022-12-22 | 上海微创心脉医疗科技(集团)股份有限公司 | Medical tubing and balloon catheter |
CN117064476A (en) * | 2023-08-30 | 2023-11-17 | 项日葵医疗科技(上海)有限公司 | Vena cava blood flow-limiting mechanism |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5308356A (en) * | 1993-02-25 | 1994-05-03 | Blackshear Jr Perry L | Passive perfusion angioplasty catheter |
US5545132A (en) * | 1993-12-21 | 1996-08-13 | C. R. Bard, Inc. | Helically grooved balloon for dilatation catheter and method of using |
US20040215142A1 (en) * | 2002-12-23 | 2004-10-28 | Georg Matheis | Appliance for cannulation of a blood vessel |
JP2005160536A (en) * | 2003-11-28 | 2005-06-23 | Nippon Sherwood Medical Industries Ltd | Balloon catheter |
KR20060073656A (en) * | 1998-10-05 | 2006-06-28 | 가부시키가이샤 가네가 | Balloon catheter and method for manufacturing same |
JP2009291557A (en) * | 2008-06-09 | 2009-12-17 | Goodman Co Ltd | Insertion aid, catheter assembly and catheter set |
JP2010167003A (en) * | 2009-01-21 | 2010-08-05 | Asahi Intecc Co Ltd | Balloon catheter |
CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
CN102793598A (en) * | 2012-08-30 | 2012-11-28 | 吕文峰 | Novel balloon expandable stent conveying system |
CN104117128A (en) * | 2014-07-18 | 2014-10-29 | 北京普益盛济科技有限公司 | Balloon catheter for mild hypothermia therapy |
CN104922784A (en) * | 2015-07-01 | 2015-09-23 | 乐普(北京)医疗器械股份有限公司 | Drug balloon catheter |
CN207137141U (en) * | 2017-02-15 | 2018-03-27 | 烟台毓璜顶医院 | A kind of cardiovascular expansion device |
CN109331322A (en) * | 2018-11-16 | 2019-02-15 | 北京久事神康医疗科技有限公司 | Encephalic sacculus dilating catheter |
CN109663202A (en) * | 2019-01-17 | 2019-04-23 | 南京普微森医疗科技有限公司 | A kind of novel cerebrovascular drug sacculus dilating catheter |
-
2019
- 2019-09-05 CN CN201910836634.3A patent/CN112439122A/en active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5308356A (en) * | 1993-02-25 | 1994-05-03 | Blackshear Jr Perry L | Passive perfusion angioplasty catheter |
US5545132A (en) * | 1993-12-21 | 1996-08-13 | C. R. Bard, Inc. | Helically grooved balloon for dilatation catheter and method of using |
KR20060073656A (en) * | 1998-10-05 | 2006-06-28 | 가부시키가이샤 가네가 | Balloon catheter and method for manufacturing same |
US20040215142A1 (en) * | 2002-12-23 | 2004-10-28 | Georg Matheis | Appliance for cannulation of a blood vessel |
JP2005160536A (en) * | 2003-11-28 | 2005-06-23 | Nippon Sherwood Medical Industries Ltd | Balloon catheter |
JP2009291557A (en) * | 2008-06-09 | 2009-12-17 | Goodman Co Ltd | Insertion aid, catheter assembly and catheter set |
JP2010167003A (en) * | 2009-01-21 | 2010-08-05 | Asahi Intecc Co Ltd | Balloon catheter |
CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
CN102793598A (en) * | 2012-08-30 | 2012-11-28 | 吕文峰 | Novel balloon expandable stent conveying system |
CN104117128A (en) * | 2014-07-18 | 2014-10-29 | 北京普益盛济科技有限公司 | Balloon catheter for mild hypothermia therapy |
CN104922784A (en) * | 2015-07-01 | 2015-09-23 | 乐普(北京)医疗器械股份有限公司 | Drug balloon catheter |
CN207137141U (en) * | 2017-02-15 | 2018-03-27 | 烟台毓璜顶医院 | A kind of cardiovascular expansion device |
CN109331322A (en) * | 2018-11-16 | 2019-02-15 | 北京久事神康医疗科技有限公司 | Encephalic sacculus dilating catheter |
CN109663202A (en) * | 2019-01-17 | 2019-04-23 | 南京普微森医疗科技有限公司 | A kind of novel cerebrovascular drug sacculus dilating catheter |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022198810A1 (en) * | 2021-03-25 | 2022-09-29 | 上海苏畅医疗科技有限公司 | Guiding catheter and guiding catheter system |
CN113144390A (en) * | 2021-04-26 | 2021-07-23 | 珠海通桥医疗科技有限公司 | Balloon catheter for intracranial CTO |
CN113368371A (en) * | 2021-06-03 | 2021-09-10 | 复旦大学附属中山医院 | Medicine carrying balloon for preventing and treating benign stricture of esophagus |
WO2022262490A1 (en) * | 2021-06-18 | 2022-12-22 | 上海微创心脉医疗科技(集团)股份有限公司 | Medical tubing and balloon catheter |
CN114939225A (en) * | 2022-06-10 | 2022-08-26 | 惠州市顺美医疗科技有限公司 | Balloon dilatation catheter |
CN117064476A (en) * | 2023-08-30 | 2023-11-17 | 项日葵医疗科技(上海)有限公司 | Vena cava blood flow-limiting mechanism |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112439122A (en) | Balloon dilatation catheter | |
US9114031B2 (en) | Method for treating a target site in a vascular body channel | |
RU2576367C2 (en) | Aspiration guide catheter for distal approach | |
EP1246660B1 (en) | Anti-recoil catheter | |
WO2021068421A1 (en) | Special catheter for thrombus aspiration from distal cerebral vessel | |
US20130102996A1 (en) | Pressure Activated Foreign Body Removal System and Method of Use | |
JP2008508936A (en) | Intravascular stent assembly and method of placement thereof | |
CN209917044U (en) | Novel cerebral vessel medicine balloon dilatation catheter | |
CN108784895B (en) | Expansion bracket system | |
US20170333237A1 (en) | Vessel access catheter | |
CN113144390B (en) | Balloon catheter for intracranial CTO | |
JP2023517575A (en) | Neurovascular catheter with enhanced flexibility | |
US20210100986A1 (en) | Vessel access catheter | |
CN108355230B (en) | Multi-guidewire drug balloon dilation catheter and method of use thereof | |
AU2017315410A1 (en) | Neurovascular stent | |
CN210541686U (en) | Plugging catheter for treating coronary artery perforation | |
US20170333670A1 (en) | Vessel access catheter | |
US20200222173A1 (en) | Vessel access catheter | |
CN107995869B (en) | Surface liquefied drug coating sacculus | |
US20180049862A1 (en) | Vessel Access Catheter | |
CN211560261U (en) | Catheter special for pumping thrombus at far end of cerebral vessel | |
EP3099371B1 (en) | Balloon with mandrel support guidewire | |
US20170333674A1 (en) | Vessel access catheter | |
CN115487399A (en) | Medical tube and balloon catheter | |
US20230073895A1 (en) | Vessel access catheter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210305 |